Sectors & Industries HealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2024)
Top diagnostic & research stocks in 2024 ranked by overall Zen Score. See the best diagnostic & research stocks to buy now, according to analyst forecasts for the diagnostics & research industry.

Industry: Diagnostics & Research

Zen Score Price Valuation Financials Forecast Earnings & Revenue Dividends Ownership Technicals

Ticker	Company	Exchange	Industry	Market Cap	Price	1d %	EBITDA	P/E	D/E
FONR	FONAR CORP	NASDAQ	Diagnostics & Research	$108.72M	$16.20	-3.63%	$25.75M	8.57x	0.28
IDXX	IDEXX LABORATORIES INC	NASDAQ	Diagnostics & Research	$39.85B	$479.57	0.68%	$1.22B	47.16x	1.20
ICLR	ICON PLC	NASDAQ	Diagnostics & Research	$24.58B	$297.93	3.37%	$1.55B	39.94x	0.84
STRR	STAR EQUITY HOLDINGS INC	NASDAQ	Diagnostics & Research	$13.80M	$0.87	0.93%	$26.87M	0.54x	0.16
RVTY	REVVITY INC	NYSE	Diagnostics & Research	$12.45B	$100.77	-0.09%	$1.25B	18.12x	0.72
A	AGILENT TECHNOLOGIES INC	NYSE	Diagnostics & Research	$39.24B	$133.91	0.89%	$1.69B	31.73x	0.77
MEDP	MEDPACE HOLDINGS INC	NASDAQ	Diagnostics & Research	$11.57B	$376.26	1.15%	$382.14M	40.90x	1.96
NEOG	NEOGEN CORP	NASDAQ	Diagnostics & Research	$2.55B	$11.78	1.46%	$188.76M	589.00x	0.46
TMO	THERMO FISHER SCIENTIFIC INC	NYSE	Diagnostics & Research	$209.10B	$548.38	0.66%	$11.06B	35.33x	1.11
CRL	CHARLES RIVER LABORATORIES INTERNATIONAL INC	NYSE	Diagnostics & Research	$11.94B	$232.56	2.55%	$1.03B	25.09x	1.26
QGEN	QIAGEN NV	NYSE	Diagnostics & Research	$9.41B	$41.22	3.05%	$688.56M	27.48x	0.61
SHC	SOTERA HEALTH CO	NASDAQ	Diagnostics & Research	$3.14B	$11.09	1.28%	$406.83M	61.61x	6.06
ENZ	ENZO BIOCHEM INC	NYSE	Diagnostics & Research	$55.84M	$1.09	0.00%	$33.74M	1.63x	0.40
LH	LABORATORY CORP OF AMERICA HOLDINGS	NYSE	Diagnostics & Research	$17.08B	$203.07	0.79%	$1.55B	42.31x	1.12
DHR	DANAHER CORP	NYSE	Diagnostics & Research	$174.63B	$236.08	0.24%	$8.04B	36.66x	0.58
CSTL	CASTLE BIOSCIENCES INC	NASDAQ	Diagnostics & Research	$538.29M	$19.61	1.55%	-$45.02M	-9.16x	0.16
TWST	TWIST BIOSCIENCE CORP	NASDAQ	Diagnostics & Research	$1.70B	$29.45	5.37%	-$169.85M	-8.16x	0.24
DGX	QUEST DIAGNOSTICS INC	NYSE	Diagnostics & Research	$14.40B	$130.09	1.28%	$1.69B	17.14x	1.22
MTD	METTLER TOLEDO INTERNATIONAL INC	NYSE	Diagnostics & Research	$25.76B	$1,199.46	0.92%	$1.17B	33.23x	-23.38
XGN	EXAGEN INC	NASDAQ	Diagnostics & Research	$24.13M	$1.40	2.19%	-$18.21M	-1.04x	1.51
WAT	WATERS CORP	NYSE	Diagnostics & Research	$17.72B	$299.23	1.06%	$1.00B	27.53x	3.02
ACRS	ACLARIS THERAPEUTICS INC	NASDAQ	Diagnostics & Research	$86.53M	$1.22	-1.61%	-$87.99M	-0.96x	0.26
SERA	SERA PROGNOSTICS INC	NASDAQ	Diagnostics & Research	$316.80M	$9.77	0.21%	-$34.76M	-8.42x	0.36
IQV	IQVIA HOLDINGS INC	NYSE	Diagnostics & Research	$41.99B	$231.34	1.42%	$3.26B	31.30x	3.37
PRPO	PRECIPIO INC	NASDAQ	Diagnostics & Research	$9.05M	$6.33	2.10%	-$4.32M	-1.40x	0.25
PSNL	PERSONALIS INC	NASDAQ	Diagnostics & Research	$63.63M	$1.26	-2.33%	-$94.95M	-0.56x	0.74
NTRA	NATERA INC	NASDAQ	Diagnostics & Research	$10.70B	$88.61	3.90%	-$383.28M	-23.44x	0.88
EXAS	EXACT SCIENCES CORP	NASDAQ	Diagnostics & Research	$11.33B	$62.41	2.38%	$52.20M	-55.23x	1.06
DRIO	DARIOHEALTH CORP	NASDAQ	Diagnostics & Research	$38.86M	$1.32	13.79%	-$54.38M	-0.68x	0.66
OLK	OLINK HOLDING AB (PUBL)	NASDAQ	Diagnostics & Research	$2.74B	$22.03	0.73%	-$20.05M	-88.12x	0.20
FLGT	FULGENT GENETICS INC	NASDAQ	Diagnostics & Research	$612.37M	$20.56	0.98%	-$134.12M	-3.65x	0.09
NEO	NEOGENOMICS INC	NASDAQ	Diagnostics & Research	$1.71B	$13.42	-0.81%	-$8.37M	-19.17x	0.79
GH	GUARDANT HEALTH INC	NASDAQ	Diagnostics & Research	$2.14B	$17.59	9.46%	-$433.31M	-4.11x	10.26
DMTK	DERMTECH INC	NASDAQ	Diagnostics & Research	$20.64M	$0.60	-7.45%	-$95.04M	-0.19x	1.13
STIM	NEURONETICS INC	NASDAQ	Diagnostics & Research	$111.29M	$3.74	-1.58%	-$22.76M	-3.56x	2.39
RDNT	RADNET INC	NASDAQ	Diagnostics & Research	$3.26B	$47.65	2.43%	$265.49M	953.00x	2.98
OCX	ONCOCYTE CORP	NASDAQ	Diagnostics & Research	$20.77M	$2.51	0.40%	-$26.05M	-0.67x	2.41
BGLC	BIONEXUS GENE LAB CORP	NASDAQ	Diagnostics & Research	$10.95M	$0.62	3.33%	-$2.49M	-3.39x	0.18
BNR	BURNING ROCK BIOTECH LTD	NASDAQ	Diagnostics & Research	$88.06M	$0.86	19.44%	N/A	-0.97x	0.35
LAB	STANDARD BIOTOOLS INC	NASDAQ	Diagnostics & Research	$736.90M	$2.54	0.79%	-$65.66M	-2.70x	-1.08
PRE	PRENETICS GLOBAL LTD	NASDAQ	Diagnostics & Research	$44.58M	$3.68	26.90%	N/A	-0.66x	0.21
APDN	APPLIED DNA SCIENCES INC	NASDAQ	Diagnostics & Research	$5.60M	$0.33	-3.79%	-$5.89M	-0.60x	1.37
XWEL	XWELL INC	NASDAQ	Diagnostics & Research	$5.65M	$1.35	-2.17%	-$24.16M	-0.20x	1.39
MDXH	MDXHEALTH SA	NASDAQ	Diagnostics & Research	$6.35M	$2.35	5.38%	-$20.47M	-0.14x	16.92
BDSX	BIODESIX INC	NASDAQ	Diagnostics & Research	$125.06M	$1.29	3.20%	-$37.10M	-2.02x	20.64
CDNA	CAREDX INC	NASDAQ	Diagnostics & Research	$423.03M	$8.17	-1.68%	-$182.19M	-2.31x	0.79
NDRA	ENDRA LIFE SCIENCES INC	NASDAQ	Diagnostics & Research	$2.76M	$0.25	1.21%	-$9.78M	-0.16x	0.19
ME	23ANDME HOLDING CO	NASDAQ	Diagnostics & Research	$222.14M	$0.46	-4.76%	-$490.64M	-0.41x	0.61
CHEK	CHECK-CAP LTD	NASDAQ	Diagnostics & Research	$13.22M	$2.26	0.00%	-$19.08M	-0.75x	0.06
ULS	UL SOLUTIONS INC	NYSE	Diagnostics & Research	N/A	$33.61	-0.71%	$519.00M	25.85x	3.15
PRPH	PROPHASE LABS INC	NASDAQ	Diagnostics & Research	$88.42M	$4.90	-6.84%	-$14.83M	-5.00x	0.86
NOTV	INOTIV INC	NASDAQ	Diagnostics & Research	$113.99M	$4.42	2.31%	$59.57M	-3.40x	2.29
AWH	ASPIRA WOMEN's HEALTH INC	NASDAQ	Diagnostics & Research	$43.20M	$3.50	0.29%	-$16.50M	-1.93x	-3.65
OPK	OPKO HEALTH INC	NASDAQ	Diagnostics & Research	$857.30M	$1.23	0.00%	-$65.62M	-4.92x	0.45
VNRX	VOLITIONRX LTD	NYSEMKT	Diagnostics & Research	$49.24M	$0.60	-2.60%	-$33.68M	-1.20x	-4.70
GENE	GENETIC TECHNOLOGIES LTD	NASDAQ	Diagnostics & Research	$547.08k	$2.37	2.16%	N/A	-0.80x	0.76
MYGN	MYRIAD GENETICS INC	NASDAQ	Diagnostics & Research	$1.66B	$18.49	-0.05%	-$186.10M	-5.81x	0.46
ISPC	ISPECIMEN INC	NASDAQ	Diagnostics & Research	$3.09M	$0.34	18.06%	-$9.02M	-0.28x	0.62
BIAF	BIOAFFINITY TECHNOLOGIES INC	NASDAQ	Diagnostics & Research	$34.54M	$3.00	7.91%	-$7.63M	-3.30x	0.69
ILMN	ILLUMINA INC	NASDAQ	Diagnostics & Research	$19.11B	$120.25	2.40%	-$608.00M	-16.38x	0.76
PMD	PSYCHEMEDICS CORP	NASDAQ	Diagnostics & Research	$15.25M	$2.66	3.31%	-$768.00k	-3.69x	0.85
MYNZ	MAINZ BIOMED NV	NASDAQ	Diagnostics & Research	$18.44M	$0.87	-3.76%	-$24.62M	-0.54x	3.74
TRIB	TRINITY BIOTECH PLC	NASDAQ	Diagnostics & Research	$13.87M	$1.81	0.28%	N/A	N/A	-3.48
MMA	ALTA GLOBAL GROUP LTD	NYSEMKT	Diagnostics & Research	N/A	$3.01	-3.68%	-$16.12M	-0.57x	-0.55
CNTG	CENTOGENE NV	NASDAQ	Diagnostics & Research	$12.97M	$0.47	3.07%	-$44.39M	-0.30x	-5.72
TTOO	T2 BIOSYSTEMS INC	NASDAQ	Diagnostics & Research	$17.42M	$3.16	6.76%	-$42.53M	-0.16x	-2.24

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Apr 2024?

According to Zen Score, the 3 best diagnostic & research stocks to buy right now are:

1. Fonar (NASDAQ:FONR)

Fonar (NASDAQ:FONR) is the top diagnostic & research stock with a Zen Score of 47, which is 19 points higher than the diagnostic & research industry average of 28. It passed 14 out of 33 due diligence checks and has strong fundamentals. Fonar has seen its stock return 3.51% over the past year, overperforming other diagnostic & research stocks by 12 percentage points.

2. Icon (NASDAQ:ICLR)

Icon (NASDAQ:ICLR) is the second best diagnostic & research stock with a Zen Score of 46, which is 18 points higher than the diagnostic & research industry average of 28. It passed 15 out of 33 due diligence checks and has strong fundamentals. Icon has seen its stock return 44.3% over the past year, overperforming other diagnostic & research stocks by 53 percentage points.

Icon has an average 1 year price target of $346.43, an upside of 16.28% from Icon's current stock price of $297.93.

Icon stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Icon, 71.43% have issued a Strong Buy rating, 28.57% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Idexx Laboratories (NASDAQ:IDXX)

Idexx Laboratories (NASDAQ:IDXX) is the third best diagnostic & research stock with a Zen Score of 46, which is 18 points higher than the diagnostic & research industry average of 28. It passed 15 out of 33 due diligence checks and has strong fundamentals. Idexx Laboratories has seen its stock lose -4.77% over the past year, overperforming other diagnostic & research stocks by 4 percentage points.

Idexx Laboratories has an average 1 year price target of $584.00, an upside of 21.78% from Idexx Laboratories's current stock price of $479.57.

Idexx Laboratories stock has a consensus Buy recommendation according to Wall Street analysts. Of the 5 analysts covering Idexx Laboratories, 60% have issued a Strong Buy rating, 0% have issued a Buy, 40% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 7 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Qiagen Nv (NYSE:QGEN)

Qiagen Nv (NYSE:QGEN) has an annual dividend yield of 3.11%, which is 2 percentage points higher than the diagnostic & research industry average of 1.38%.

Qiagen Nv's dividend payout ratio of 85.3% indicates that its dividend yield is sustainable for the long-term.

2. Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 2.21%, which is 1 percentage points higher than the diagnostic & research industry average of 1.38%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 37.4% indicates that its dividend yield is sustainable for the long-term.

3. Laboratory Of America Holdings (NYSE:LH)

Laboratory Of America Holdings (NYSE:LH) has an annual dividend yield of 1.42%, which is the same as the diagnostic & research industry average of 1.38%. Laboratory Of America Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Laboratory Of America Holdings's dividend has not shown consistent growth over the last 10 years.

Laboratory Of America Holdings's dividend payout ratio of 60% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks up?

Diagnostic & research stocks were up 1.24% in the last day, and down -2.33% over the last week.

We couldn't find a catalyst for why diagnostic & research stocks are up.

What are the most undervalued diagnostic & research stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued diagnostic & research stocks right now are:

1. Star Equity Holdings (NASDAQ:STRR)

Star Equity Holdings (NASDAQ:STRR) is the most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Star Equity Holdings has a valuation score of 71, which is 49 points higher than the diagnostic & research industry average of 22. It passed 5 out of 7 valuation due diligence checks.

Star Equity Holdings's stock has gained 8.88% in the past year. It has overperformed other stocks in the diagnostic & research industry by 17 percentage points.

2. Enzo Biochem (NYSE:ENZ)

Enzo Biochem (NYSE:ENZ) is the second most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Enzo Biochem has a valuation score of 71, which is 49 points higher than the diagnostic & research industry average of 22. It passed 5 out of 7 valuation due diligence checks.

Enzo Biochem's stock has dropped -57.09% in the past year. It has underperformed other stocks in the diagnostic & research industry by -49 percentage points.

3. Fonar (NASDAQ:FONR)

Fonar (NASDAQ:FONR) is the third most undervalued diagnostic & research stock based on WallStreetZen's Valuation Score. Fonar has a valuation score of 71, which is 49 points higher than the diagnostic & research industry average of 22. It passed 5 out of 7 valuation due diligence checks.

Fonar's stock has gained 3.51% in the past year. It has overperformed other stocks in the diagnostic & research industry by 12 percentage points.

Are diagnostic & research stocks a good buy now?

46.81% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 12.42% over the next year.

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 36.48x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.